Sci.D., Professor of Internal Molecular and Medicine Genetics, University of Texas Southwestern Medical Center. Alnylam expects to progress its ALN-PCS plan toward the clinic with a goal of initiating a Stage I clinical trial in 2011. Source Alnylam Pharmaceuticals.. Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today the presentation of new announced pre-medical data from its hypercholesterolemia program, performed in collaboration with researchers at the University of Texas Southwestern INFIRMARY at Dallas.We determined a difference of 0.15 liters from that in the placebo group would be clinically meaningful. After accounting for potential dropout and imperfect compliance,10 we determined that 130 patients per group would provide a power of 90 percent for the first step of the testing treatment under most scenarios.11 The mark sample size was expected to offer a power of around 93 percent to identify a big change at the two-sided 0.05 level for the hypothesized difference of 0.15 liters between research groups at 60 weeks. All analyses are based on the intention-to-treat principle with data from all individuals who underwent randomization.